Building on Edinburgh’s Translational Platform (BOETP)
Lead Research Organisation:
University of Edinburgh
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- University of Edinburgh (Lead Research Organisation)
- Alfacyte Ltd (Collaboration)
- Complutense University of Madrid (Collaboration)
- Elasmogen Ltd (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Novartis (Collaboration)
- Syncona (Collaboration)
- UCB Pharma (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- Galecto Biotech (Collaboration)
People |
ORCID iD |
Publications
Dwyer BJ
(2021)
TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
in Journal of hepatology
Ledahawsky L
(2022)
The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo
in The FEBS Journal
Pinto Torres JE
(2020)
Structural and kinetic characterization of Trypanosoma congolense pyruvate kinase.
in Molecular and biochemical parasitology
Moroni F
(2019)
Safety profile of autologous macrophage therapy for liver cirrhosis.
in Nature medicine
Mitchell AR
(2018)
Redox regulation of pyruvate kinase M2 by cysteine oxidation and S-nitrosation.
in The Biochemical journal
Zhong W
(2019)
Pyruvate Kinase Regulates the Pentose-Phosphate Pathway in Response to Hypoxia in Mycobacterium tuberculosis.
in Journal of molecular biology
McNae IW
(2021)
Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice.
in Nature communications
Moshtael H
(2019)
Dynamic text presentation on smart glasses: A pilot evaluation in age-related macular degeneration
in British Journal of Visual Impairment
| Description | British Heart Foundation (SIMLR CIC5) |
| Amount | £300,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | CSO grant (CSF1-FC CIC5) |
| Amount | £26,955 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 09/2019 |
| Description | Developmental Pathway Funding Scheme |
| Amount | £2,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | EU funded partnership with Gdansk to support PhD |
| Amount | £120,000 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | |
| Description | Enterprise Fellowship |
| Amount | £80,000 (GBP) |
| Organisation | Royal Academy of Engineering |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2024 |
| Description | Galecto - Anti-Galectin |
| Amount | £54,256 (GBP) |
| Organisation | Galecto Biotech |
| Sector | Private |
| Country | Sweden |
| Start | 01/2018 |
| End | 06/2018 |
| Description | Galecto continued funding for postdoc: IDF project |
| Amount | £35,000 (GBP) |
| Organisation | Galecto Biotech |
| Sector | Private |
| Country | Sweden |
| Start | 09/2018 |
| End | 12/2018 |
| Description | IPO Access Fund |
| Amount | £10,000 (GBP) |
| Organisation | Intellectual Property Office (IPO) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Institutional Strategy Support Fund 3: CSF1-FC |
| Amount | £29,281 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 12/2019 |
| Description | MRC DPFS (ENPP6 CIC5) |
| Amount | £124,977 (GBP) |
| Funding ID | MR/R02300X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2020 |
| Description | MRC DPFS (Forbes) |
| Amount | £3,000,000 (GBP) |
| Funding ID | MR/L014335/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 11/2025 |
| Description | Manipulating microglial/macrophage function via CSF-1R to improve functional recovery and neuroplasticity after stroke |
| Amount | £277,547 (GBP) |
| Organisation | Brain Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2023 |
| Description | Medical Research Council CIC (ENPP6 CIC5) |
| Amount | £95,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 12/2017 |
| Description | Newton Mobility Grant (PFK1) |
| Amount | £11,000 (GBP) |
| Organisation | Royal Society of Medicine |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2020 |
| Description | Precision Medicine PhD studentship |
| Amount | £85,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | RSE Fellowship (Chicken bioreactor CIC5) |
| Amount | £60,000 (GBP) |
| Organisation | Royal Society of Edinburgh (RSE) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2018 |
| Description | Resilience Fund |
| Amount | £10,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Scottish Edge Award (Underwood) Wild card winner |
| Amount | £10,000 (GBP) |
| Organisation | Edge Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Seed investment (Underwood) |
| Amount | £150,000 (GBP) |
| Organisation | Techstart Ventures |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Selcia - PFK1 CiC5 |
| Amount | £120,000 (GBP) |
| Organisation | Selcia |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | UCB: (IPF) |
| Amount | £89,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2019 |
| Description | WT iTPA accelerating funding Walkinshaw |
| Amount | £20,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 10/2020 |
| Description | WT-iTPA (Baker) |
| Amount | £19,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 11/2020 |
| Description | iCURE Programme |
| Amount | £35,000 (GBP) |
| Organisation | SETsquared Partnership |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Title | Knock down fly lines |
| Description | Generation of SFXN3 over-expression and SFXN3 knock-down fly lines |
| Type Of Material | Cell line |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Impact unknown |
| Title | Knockout mice |
| Description | Establishment (through the International Mouse Phenotyping Consortium; IMPC) and characterisation of SFXN3 knockout mice, including aged populations of animals |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | unknown impact |
| Title | Novel Parkinson's disease fly lines (Gillingwater) |
| Description | Establishment of novel Parkinson's disease fly lines in Edinburgh |
| Type Of Material | Cell line |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Impact unknown |
| Title | New Proteomics database |
| Description | Extensive new proteomics databases of molecular changes occurring downstream of SFXN3 in the nervous system |
| Type Of Material | Data analysis technique |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | unknown impact to date |
| Description | Alfacyte - Chicken bioreactor CIC5 |
| Organisation | Alfacyte Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project plan / IP |
| Collaborator Contribution | Company agreed to put their sequences into PGCs during the course of the project. |
| Impact | No outputs - project in early stages. |
| Start Year | 2017 |
| Description | Complutense University of Madrid (McColl) |
| Organisation | Complutense University of Madrid |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Moro lab, Complutense University of Madrid - collaboration initiated prior to CiC project and PhD visiting PhD student from Moro lab contributed to collection of initial data. MTA/CDA signed with Madrid to enable sharing of data and tissue samples. Collaboration is ongoing and contributed to award of a Fondation Leducq grant |
| Collaborator Contribution | Moro lab, Complutense University of Madrid - collaboration initiated prior to CiC project and PhD visiting PhD student from Moro lab contributed to collection of initial data. MTA/CDA signed with Madrid to enable sharing of data and tissue samples. Collaboration is ongoing and contributed to award of a Fondation Leducq grant |
| Impact | Contributed to grant award |
| Start Year | 2017 |
| Description | Elasmogen - Chicken bioreactor |
| Organisation | Elasmogen Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project idea / IP |
| Collaborator Contribution | Company putting their sequences into PGCs during course of project. |
| Impact | No outcomes - project in early stages. |
| Start Year | 2017 |
| Description | Galecto - Anti-galectin CIC5 |
| Organisation | Galecto Biotech |
| Country | Sweden |
| Sector | Private |
| PI Contribution | Project / academic IP |
| Collaborator Contribution | Pipeline |
| Impact | Project in early stages so outcome will be reported next year. |
| Start Year | 2017 |
| Description | Galecto BioTech further funding |
| Organisation | Galecto Biotech |
| Country | Sweden |
| Sector | Private |
| PI Contribution | underpinning science for project provided by UoE academics |
| Collaborator Contribution | Galecto - providing expertise, joint submission on funding applications and financial contribution to staff / research. Discussion re spinout underway between University and Galecto |
| Impact | no outputs to date. Spin out under discussion |
| Start Year | 2018 |
| Description | Moon Lab at Kings College London |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Moon lab, King's College London - initiated on back of data generated in CiC project to develop project proposal for assessing longer-term effects of CSF1-Fc using a stroke model and behavioural outcomes used by the Moon lab. Has enabled a grant application to Brain Research UK |
| Collaborator Contribution | Moon lab, King's College London - initiated on back of data generated in CiC project to develop project proposal for assessing longer-term effects of CSF1-Fc using a stroke model and behavioural outcomes used by the Moon lab. Has enabled a grant application to Brain Research UK |
| Impact | No outputs to date |
| Start Year | 2019 |
| Description | Novartis (CSF1-FC CIC5_ |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | Novartis currently hold an exclusive option to a license for human indications to exploit CSF1-Fc as defined in PCT/GB2014/050595. Novartis indicated support for further regenerative medicine applications during CiC proposal submission |
| Collaborator Contribution | Novartis indicated support for further regenerative medicine applications during CiC proposal submission |
| Impact | No outputs to report to date |
| Start Year | 2017 |
| Description | Syncona Ltd (Forbes) |
| Organisation | Syncona |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Syncona Ltd invested £26m in Resolution Therapeutics Ltd (Stuart Forbes) |
| Collaborator Contribution | Company/spin out/founders of company |
| Impact | Outcomes to be reported in following years. Recent investment |
| Start Year | 2020 |
| Description | UCB partnership (Anti Galectin CIC5) |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discovery research |
| Collaborator Contribution | Expertise |
| Impact | Current partnership - no outcomes to report to date |
| Start Year | 2018 |
| Description | University of Glasgow (Gillingwater) |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Underpinning science of project |
| Collaborator Contribution | UoG provided world leading mitochondrial expertise which means project is better placed to explore the molecular mechanisms through which SFXN3 regulates neurodegeneration |
| Impact | Collaboration will progress project and aid further funding |
| Start Year | 2018 |
| Title | A READING SYSTEM, TEXT DISPLAY METHOD AND APPARATUS |
| Description | A reading system comprises an apparatus comprising a screen and a processor configured to display a sequence of text to a reader in a reading process; and at least one processing resource configured to obtain reading data representative of at least one property of the text and/or the reading process, and to process the reading data to identify changes in the reading data over time that may be indicative of visual or neurological deterioration and/or the presence of at least one condition in the reader. |
| IP Reference | WO2018046957 |
| Protection | Patent granted |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | No impact to date. |
| Title | MACROPHAGE-BASED THERAPY FOR USE IN THE TREATMENT OF LIVER INJURY |
| Description | The present invention relates to alternatively activated macrophages (AAMs) for use in the treatment of liver injury and methods of treating and preventing liver injury using AAMs. |
| IP Reference | WO2018051136 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | Significant funding from one tier UK investor |
| Title | MATERIALS AND METHODS FOR THE TREATMENT OF VASCULAR DISEASE |
| Description | The invention provides a method of treating a vascular condition within a subject comprising administering a therapeutic agent to said subject that is capable of modulating the expression levels of a long non-coding RNA (IncRNA) selected from the group consisting of lncRNA2, lncRNA4, lncRNA5, lncRNA6, ncRNA7 and ncRNA8 as defined in figure 39. |
| IP Reference | WO2016146996 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | No impact to date |
| Company Name | Resolution Therapeutics Ltd |
| Description | Resolution Therapeutics Ltd is based on a decade of research from the Forbes lab at the Centre for Regenerative Medicine and will be housed within the Centre building at Edinburgh BioQuarter. Cirrhosis is caused by long-term damage to the liver. More than 4,000 people a year in the UK die from cirrhosis with around 700 people needing a liver transplant. There are currently no therapies available and patients are at risk of progressing to decompensated cirrhosis, where the liver can no longer cope and the patient needs a transplant. Resolution Therapeutics Ltd is developing cell treatments to repair organ damage - including end-stage chronic liver disease. It has received funding of £26.6 million from Syncona Ltd, a specialist healthcare investment company. The investment is expected to enable Resolution to gain early clinical data for its first product. The new biopharmaceutical company is developing macrophage cell therapies. Macrophages are immune system cells involved in responses to injury, including the wound-healing process. Resolution is exploiting the ability of macrophages to stimulate organ repair following damage caused by disease. Resolution's first programme is an engineered macrophage to treat patients with compensated liver cirrhosis - where the liver is badly damaged but still functioning. |
| Year Established | 2017 |
| Impact | Received £26m series 1 investment in late 2020 from VC therefore impacts will be reported in following years. |
| Website | https://resolution-tx.com/ |
| Company Name | BRIGHTPAGE TECHNOLOGIES LTD |
| Description | Software development company - predictive text for reading |
| Year Established | 2020 |
| Impact | Nothing to report |
| Website | https://www.brightpage.tech/ |
| Description | Anatomy@Edinburgh public engagement programme |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Both Professor Gillingwater and Dr Wishart have engaged in extensive public engagement activities over the duration of the CiC award, during which we were able to communicate our work concerning neurodegeneration to a range of diverse audiences. Many of these activities were coordinated through the Anatomy@Edinburgh public engagement programme (including visits to, and from, primary and secondary school children). Further details can be found at: https://www.ed.ac.uk/biomedical-sciences/anatomy |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.ed.ac.uk/biomedical-sciences/anatomy |
| Description | Research and combined patient group meetings |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Both applicants have been invited to chair sessions and present research at several combined research/patient group meetings for Neuronal Ceroid Lipofuscinoses (Batten Disease) and spinal muscular atrophy (SMA). |
| Year(s) Of Engagement Activity | 2018 |